Lyell Immunopharma, Inc. (LYEL) — SEC Filings
Lyell Immunopharma, Inc. (LYEL) — 37 SEC filings. Latest: EFFECT (Apr 15, 2026). Includes 19 8-K, 6 10-Q, 4 SC 13G/A.
View Lyell Immunopharma, Inc. on SEC EDGAR
Overview
Lyell Immunopharma, Inc. (LYEL) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 15, 2026: Lyell Immunopharma, Inc. filed an EFFECT form on April 15, 2026, indicating the effectiveness of a filing related to their securities. The filing, with accession number 9999999995-26-001185, was accepted at 00:15:12. The effectiveness date is listed as April 14, 2026.
Sentiment Summary
Across 37 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Lyell Immunopharma, Inc. is neutral.
Filing Type Overview
Lyell Immunopharma, Inc. (LYEL) has filed 1 EFFECT, 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 1 8-K/A, 4 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (37)
Risk Profile
Risk Assessment: Of LYEL's 28 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $30K |
| Net Income | -$133.725M |
| EPS | N/A |
| Debt-to-Equity | 0.24 |
| Cash Position | $123.575M |
| Operating Margin | N/A |
| Total Assets | $407.965M |
| Total Debt | $78.844M |
Industry Context
Lyell Immunopharma operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on advanced cell therapies for cancer. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Key trends include the increasing focus on personalized medicine, the development of novel immunotherapies, and the consolidation of smaller players by larger pharmaceutical companies seeking innovative pipelines.
Top Tags
8-K (4) · Biotechnology (4) · corporate-governance (4) · executive-compensation (4) · 10-Q (4) · regulatory-filing (3) · board-changes (3) · equity-sale (3) · regulation-fd (3) · Reverse Stock Split (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Effectiveness Date | 2026-04-14 | The date the filing officially became active. |
| Acceptance Date | 2026-04-15 | The date the SEC accepted the filing. |
| Net Loss | $133.725M | for the nine months ended September 30, 2025, an improvement from $151.059M in 2024 |
| Cash and Cash Equivalents | $123.575M | as of September 30, 2025, up from $105.597M at December 31, 2024 |
| Proceeds from PIPE Financing | $50.000M | equity issuance during the nine months ended September 30, 2025 |
| Research and Development Expenses | $106.476M | for the nine months ended September 30, 2025, down from $122.935M in 2024 |
| Revenue | $30K | for the nine months ended September 30, 2025, indicating pre-commercial stage |
| Reverse Stock Split | 1-for-20 | effected on May 30, 2025 |
| Shares Outstanding | 21,218,217 | as of November 10, 2025 |
| Total Assets | $407.965M | as of September 30, 2025, down from $490.859M at December 31, 2024 |
| SEC File Number | 001-40502 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 83-1300510 | Company's tax identification number. |
| Net Cash Used in Operating Activities | $89.196M | For the six months ended June 30, 2025, indicating significant cash burn. |
| Marketable Securities | $177.986M | At June 30, 2025, down from $264.930M at December 31, 2024. |
| Reverse Stock Split Ratio | 1-for-20 | Effected on May 30, 2025, impacting share count and price. |
Frequently Asked Questions
What are the latest SEC filings for Lyell Immunopharma, Inc. (LYEL)?
Lyell Immunopharma, Inc. has 37 recent SEC filings from Jan 2024 to Apr 2026, including 19 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LYEL filings?
Across 37 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Lyell Immunopharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lyell Immunopharma, Inc. (LYEL) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lyell Immunopharma, Inc.?
Key financial highlights from Lyell Immunopharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LYEL?
The investment thesis for LYEL includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lyell Immunopharma, Inc.?
Executive information for Lyell Immunopharma, Inc. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Lyell Immunopharma, Inc. stock?
Of LYEL's 28 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Lyell Immunopharma, Inc.?
Forward guidance and predictions for Lyell Immunopharma, Inc. are extracted from SEC filings as they are enriched.